SmithKline Beecham consumer health care profit margins nearing 20% goal -- Leschley.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE CONSUMER HEALTH CARE PROFIT MARGINS NEARING 20% GOAL, SmithKline Beecham CEO Jan Leschley noted at an April 16 "New Ventures in Health Care" conference at the Wharton School. The company's trading profit margin for the consumer health care sector was 16.7% in 1997, up .9% from the year before. While "it is not the [27%] margin that you have" in the pharmaceutical sector, Leschley acknowledged, it is "getting closer and closer to 20%, which is our goal."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning